Twin Capital Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$812K Buy
+4,430
New +$816K 0.1% 187
2025
Q4
Sell
-6,788
Closed -$951K 253
2025
Q3
$951K Sell
6,788
-5,246
-44% -$709K 0.12% 168
2025
Q2
$1.51M Buy
12,034
+492
+4% +$61.3K 0.16% 148
2025
Q1
$1.58M Buy
11,542
+3,029
+36% +$433K 0.18% 133
2024
Q4
$1.3M Buy
8,513
+63
+0.7% +$10.6K 0.14% 147
2024
Q3
$1.64M Sell
8,450
-68
-0.8% -$14.2K 0.18% 140
2024
Q2
$1.97M Buy
8,518
+260
+3% +$56.5K 0.23% 121
2024
Q1
$1.78M Sell
8,258
-593
-7% -$139K 0.22% 128
2023
Q4
$2.29M Sell
8,851
-278
-3% -$68.3K 0.3% 101
2023
Q3
$2.35M Sell
9,129
-534
-6% -$143K 0.34% 86
2023
Q2
$2.75M Sell
9,663
-359
-4% -$107K 0.36% 73
2023
Q1
$2.79M Sell
10,022
-1,558
-13% -$431K 0.38% 79
2022
Q4
$3.21M Buy
11,580
+1,830
+19% +$517K 0.42% 70
2022
Q3
$2.6M Buy
+9,750
New +$2.07M 0.35% 81
2021
Q4
Sell
-1,547
Closed -$438K 284
2021
Q3
$438K Buy
1,547
+18
+1% +$5.9K 0.04% 279
2021
Q2
$529K Hold
1,529
0.05% 262
2021
Q1
$428K Sell
1,529
-11,298
-88% -$3.05M 0.04% 280
2020
Q4
$3.14M Sell
12,827
-388
-3% -$100K 0.29% 107
2020
Q3
$3.75M Sell
13,215
-171
-1% -$47.7K 0.34% 87
2020
Q2
$3.58M Sell
13,386
-943
-7% -$283K 0.34% 90
2020
Q1
$4.53M Buy
14,329
+10
+0.1% +$3.04K 0.49% 56
2019
Q4
$4.25M Sell
14,319
-2,200
-13% -$610K 0.36% 93
2019
Q3
$3.85M Sell
16,519
-1,110
-6% -$258K 0.28% 121
2019
Q2
$4.12M Sell
17,629
-10,335
-37% -$2.39M 0.29% 120
2019
Q1
$6.61M Buy
27,964
+70
+0.3% +$22K 0.33% 98
2018
Q4
$8.39M Sell
27,894
-1,516
-5% -$484K 0.47% 63
2018
Q3
$10.4M Buy
29,410
+2,270
+8% +$782K 0.48% 59
2018
Q2
$7.88M Buy
27,140
+340
+1% +$95.6K 0.4% 80
2018
Q1
$7.34M Sell
26,800
-7,522
-22% -$2.33M 0.38% 88
2017
Q4
$10.9M Buy
34,322
+8,302
+32% +$2.66M 0.54% 53
2017
Q3
$8.15M Buy
26,020
+2,590
+11% +$767K 0.43% 71
2017
Q2
$6.36M Buy
23,430
+1,180
+5% +$312K 0.37% 80
2017
Q1
$6.08M Sell
22,250
-8,041
-27% -$2.27M 0.38% 82
2016
Q4
$8.59M Sell
30,291
-2,226
-7% -$660K 0.55% 48
2016
Q3
$10.2M Buy
32,517
+17,537
+117% +$5.19M 0.68% 33
2016
Q2
$3.62M Sell
14,980
-900
-6% -$237K 0.27% 118
2016
Q1
$4.13M Buy
15,880
+760
+5% +$201K 0.32% 92
2015
Q4
$4.63M Buy
15,120
+1,300
+9% +$374K 0.38% 74
2015
Q3
$4.03M Buy
13,820
+250
+2% +$82.6K 0.38% 77
2015
Q2
$5.48M Sell
13,570
-4,580
-25% -$1.84M 0.49% 62
2015
Q1
$7.66M Buy
18,150
+820
+5% +$323K 0.67% 38
2014
Q4
$5.88M Buy
17,330
+670
+4% +$217K 0.56% 51
2014
Q3
$5.51M Buy
16,660
+1,511
+10% +$498K 0.56% 43
2014
Q2
$4.78M Buy
15,149
+2,780
+22% +$837K 0.48% 52
2014
Q1
$3.78M Sell
12,369
-100
-0.8% -$31.7K 0.4% 69
2013
Q4
$3.49M Buy
12,469
+100
+0.8% +$25.9K 0.37% 79
2013
Q3
$2.98M Buy
12,369
+650
+6% +$145K 0.32% 98
2013
Q2
$2.52M Buy
+11,719
New +$2.5M 0.27% 111

Other funds holding BIIB

Twin Capital Management's BIIB Position: Q1 2026 in Review

Twin Capital Management opened a new position in Biogen (BIIB) in Q1 2026: 4,430 shares worth $812K. The stake represents 0.1% of the portfolio and ranks #187 among its holdings. This is a return to the name: Twin Capital Management previously reported a position in BIIB as recently as Q3 2025.

Twin Capital Management first reported a position in BIIB in Q2 2013 and has held it in 48 quarters since. The position peaked at $10.9M in Q4 2017. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Twin Capital Management held 4,430 shares of Biogen worth $812K as of Q1 2026.
  • Biogen was a new Twin Capital Management position in Q1 2026.
  • Biogen made up 0.1% of Twin Capital Management's portfolio in Q1 2026, its #187 holding.
  • Twin Capital Management first reported a position in Biogen in Q2 2013 and has held it in 48 quarters since.
  • Twin Capital Management's Biogen position peaked at $10.9M in Q4 2017.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.